{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD). Some disease-associated mutations directly affect LRRK2 kinase activity and inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to LRRK2 kinase activity, which is directly impacted by the G2019S mutation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "The assays used (binding and enzymatic assays) are relevant to assessing kinase activity, which is central to the disease mechanism of PD associated with LRRK2 mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper includes both TR-FRET competitive binding assays and in vitro kinase activity assays, which are standard techniques for assessing ATP affinity and kinase activity, respectively."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step_4a": {
            "step_name": "Sub-step 4a: Statistical Analyses",
            "extracted_paper_info": "All assays were performed using either three or four replicates for each data point represented.",
            "judgment": "Yes",
            "reasoning": "The paper mentions the use of replicates, which is essential for statistical analysis, although specific statistical tests or p-values are not detailed."
          },
          "sub_step_4b": {
            "step_name": "Sub-step 4b: No OddsPath Calculation",
            "judgment": "N/A",
            "reasoning": "Since statistical analyses were deemed sufficient in sub-step 4a, this sub-step is not applicable."
          },
          "sub_step_4c": {
            "step_name": "Sub-step 4c: Correlate OddsPath",
            "judgment": "N/A",
            "reasoning": "Since OddsPath calculation is not directly mentioned or applicable based on the provided information, this sub-step is not applicable."
          }
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence supports the pathogenicity of the G2019S variant in LRRK2. The variant shows higher kinase activity and altered ATP affinity, which are consistent with a pathogenic effect on LRRK2 function, contributing to Parkinson's disease."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson’s disease (PD). Some disease-associated mutations directly affect LRRK2 kinase activity and inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to LRRK2 kinase activity, which is directly impacted by the I2020T mutation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "The assays used (binding and enzymatic assays) are relevant to assessing kinase activity, which is central to the disease mechanism of PD associated with LRRK2 mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper includes both TR-FRET competitive binding assays and in vitro kinase activity assays, which are standard techniques for assessing ATP affinity and kinase activity, respectively."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step_4a": {
            "step_name": "Sub-step 4a: Statistical Analyses",
            "extracted_paper_info": "All assays were performed using either three or four replicates for each data point represented.",
            "judgment": "Yes",
            "reasoning": "The paper mentions the use of replicates, which is essential for statistical analysis, although specific statistical tests or p-values are not detailed."
          },
          "sub_step_4b": {
            "step_name": "Sub-step 4b: No OddsPath Calculation",
            "judgment": "N/A",
            "reasoning": "Since statistical analyses were deemed sufficient in sub-step 4a, this sub-step is not applicable."
          },
          "sub_step_4c": {
            "step_name": "Sub-step 4c: Correlate OddsPath",
            "judgment": "N/A",
            "reasoning": "Since OddsPath calculation is not directly mentioned or applicable based on the provided information, this sub-step is not applicable."
          }
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence supports the pathogenicity of the I2020T variant in LRRK2. The variant shows lower kinase activity and higher ATP affinity, which are consistent with a pathogenic effect on LRRK2 function, contributing to Parkinson's disease."
    }
  ]
}